0001214659-19-008005.txt : 20191226 0001214659-19-008005.hdr.sgml : 20191226 20191226181506 ACCESSION NUMBER: 0001214659-19-008005 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191223 FILED AS OF DATE: 20191226 DATE AS OF CHANGE: 20191226 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Christensen Jamie CENTRAL INDEX KEY: 0001599324 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35921 FILM NUMBER: 191311346 MAIL ADDRESS: STREET 1: C/O MIRATI THERAPEUTICS, INC. STREET 2: 9393 TOWNE CENTRE DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Mirati Therapeutics, Inc. CENTRAL INDEX KEY: 0001576263 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462693615 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9393 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-332-3410 MAIL ADDRESS: STREET 1: 9393 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 marketforms-47018.xml PRIMARY DOCUMENT X0306 4 2019-12-23 0001576263 Mirati Therapeutics, Inc. MRTX 0001599324 Christensen Jamie C/O MIRATI THERAPEUTICS, INC. 9393 TOWNE CENTRE DRIVE, STE 200 SAN DIEGO CA 92121 false true false false EVP, Chief Scientific Officer Common Stock 2019-12-23 4 M false 2499 5.50 A 11658 D Common Stock 2019-12-23 4 S false 2499 125.00 D 9159 D Common Stock 2019-12-23 4 M false 4167 5.40 A 13326 D Common Stock 2019-12-23 4 S false 4167 125.00 D 9159 D Employee Stock Option (Right to Buy) 5.50 2019-12-23 4 M false 2499 0 D 2026-10-26 Common Stock 2499 15003 D Employee Stock Option (Right to Buy) 5.40 2019-12-23 4 M false 4167 0 D 2027-01-25 Common Stock 4167 28125 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2018. Includes 256 shares acquired under the ESPP Purchase on 05/31/2019 and 114 shares acquired under the ESPP purchase on 11/29/2019. 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of theshares subject to the Option shall vest each month thereafter until fully vested. /s/ Vickie Reed, Attorney-in-Fact 2019-12-26